Summary & Overview
HCPCS J1414: Injection of fidanacogene elaparvovec-dzkt, per therapeutic dose
HCPCS Level II code J1414 identifies the injectable gene therapy fidanacogene elaparvovec-dzkt, billed per therapeutic dose. This designation matters nationally as single-administration gene therapies carry distinct coverage, coding, and payment implications across commercial and public payers. Payers must address prior authorization, site-of-care routing, and high-cost administration logistics for these one-time therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage and coding considerations, typical billing workflows for a one-time injectable gene therapy, and the types of benchmarks and policy elements insurers commonly apply. The publication outlines common clinical and administrative touchpoints: the therapeutic-dose billing construct, expected site-of-service for administration, and payer-focused issues such as medical necessity review and benefit pathway alignment.
The report provides national context rather than state-specific guidance. It summarizes what stakeholders need to know about documenting the administration, common modifier usage patterns (listed separately), and where to look for payer-specific policy updates. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J1414 represents the administration of fidanacogene elaparvovec-dzkt, billed per therapeutic dose. This code denotes a gene therapy product delivered as an injection intended to provide a one-time therapeutic dose.
Service type: Injectable gene therapy, single therapeutic dose
Typical site of service: Outpatient specialty clinic or hospital outpatient infusion/administration area
Clinical & Coding Specifications
Clinical Context
A 28-year-old male with severe hemophilia B and a history of frequent spontaneous bleeding events presents for administration of gene therapy. He has been evaluated by a multidisciplinary team including a hematologist, infusion nurse, and genetic counselor. Pre-procedure workup includes baseline laboratory testing (factor IX activity, liver function tests, viral serologies), screening for pre-existing neutralizing antibodies to the AAV vector, informed consent, and documentation of eligibility criteria. On the day of service, the patient undergoes a single intravenous therapeutic dose of J1414 (fidanacogene elaparvovec-dzkt) administered under monitored outpatient infusion conditions with vital sign monitoring and post-infusion observation for acute infusion reactions. The typical clinical workflow includes pre-medication as indicated, administration by an infusion-trained registered nurse, monitoring by the treating hematology team, and follow-up visits to assess factor activity, liver enzymes, and bleeding phenotype changes. The typical site of service is an outpatient infusion center or ambulatory specialty clinic with capability for emergency management and extended observation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard reporting | Use when no special circumstances apply and global reporting is appropriate. |